Snapshot from Aug 01, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ADMA Biologics securities class action
Regulatory class action lawsuit

ADMA Biologics securities class action

Analysis based on 6 articles · First reported Jul 29, 2026 · Last updated Aug 01, 2026

Sentiment
-30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit could negatively affect ADMA Biologics' stock price and investor confidence, as allegations of securities fraud and channel stuffing may lead to financial penalties and reputational damage. The market may react to the uncertainty and potential legal costs, though the impact is likely limited to the company and its sector.

Biotechnology Pharmaceuticals
Event Summary

Kahn Swick & Foti, LLC (KSF) has filed a class action securities lawsuit against ADMA Biologics, Inc. and certain of its executives. The lawsuit, Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-04793, is pending in the United States — United States District Court for the District of New Jersey. The complaint alleges that ADMA Biologics failed to disclose material information in its offering documents, including an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 are included in the class. The deadline to apply for lead plaintiff is August 10, 2026.

Key Actions
100 Kahn Swick & Foti notified investors of lawsuit ADMA Biologics
Entities Involved
stock
ADMA Biologics
ADMA Biologics is the defendant in the class action lawsuit, facing allegations of securities fraud and misleading investors. The lawsuit could result in financial damages, regulatory scrutiny, and a decline in stock price.
Importance 100.0 Sentiment -50.0
priv
Kahn Swick & Foti
Kahn Swick & Foti is the law firm representing the class of investors in the lawsuit. The firm stands to gain from a successful settlement or judgment, and its reputation is enhanced by taking on high-profile securities cases.
Importance 80.0 Sentiment 20.0
govactor
United States — United States District Court for the District of New Jersey
The court is the venue for the class action lawsuit, where the case will be adjudicated. The court's decisions will determine the outcome of the litigation, including any potential settlement or judgment.
Importance 50.0 Sentiment 0.0
per
Lewis Kahn
Lewis Kahn is the managing partner at Kahn Swick & Foti and is actively involved in the case, serving as a contact for investors. His role is to lead the litigation and seek recovery for the class.
Importance 40.0 Sentiment 10.0
per
Charles Foti
Charles Foti, a partner at Kahn Swick & Foti and former Louisiana Attorney General, is involved in the case. His involvement adds credibility to the litigation but has no direct financial impact on him.
Importance 30.0 Sentiment 10.0
Relationships
ADMA Biologics related ↔ Kahn Swick & Foti
ADMA Biologics related ↔ United States — United States District Court for the District of New Jersey
Kahn Swick & Foti related ↔ United States — United States District Court for the District of New Jersey
Kahn Swick & Foti related ↔ Lewis Kahn
Kahn Swick & Foti related ↔ Charles Foti
Lewis Kahn managing partner ↔ Charles Foti Lewis Kahn is the Managing Partner and a founding partner of Kahn Swick & Foti, LLC, a law firm where Charles Foti is a
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.